Weiwei Tang

7.0k total citations · 4 hit papers
122 papers, 4.3k citations indexed

About

Weiwei Tang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Weiwei Tang has authored 122 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 35 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Weiwei Tang's work include Circular RNAs in diseases (24 papers), MicroRNA in disease regulation (18 papers) and Cancer-related molecular mechanisms research (16 papers). Weiwei Tang is often cited by papers focused on Circular RNAs in diseases (24 papers), MicroRNA in disease regulation (18 papers) and Cancer-related molecular mechanisms research (16 papers). Weiwei Tang collaborates with scholars based in China, Germany and United States. Weiwei Tang's co-authors include Dawei Rong, Xuehao Wang, Hongyong Cao, Fan Wu, Qian Wang, Handong Sun, Ye Cheng, Wenling Zhang, Kai Fu and Zhouxiao Li and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Weiwei Tang

120 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

2020 752 citations Weiwei Tang, Ye Cheng et al. Signal Transduction and Targeted Therapy profile →
An emerging function of circRNA-miRNAs-mRNA axis in human diseases

2017 399 citations Dawei Rong, Handong Sun et al. profile →
Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing

2022 194 citations Xiaopei Hao, Zhiying Zheng et al. profile →
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives

2024 84 citations Dong-Min Shi, Jinhua Song et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weiwei Tang China	32	2.7k	2.0k	667	574	564	122	4.3k
Hongping Xia China	37	3.2k 1.2×	2.4k 1.2×	683 1.0×	327 0.6×	604 1.1×	97	4.5k
Cun Wang China	37	3.6k 1.3×	2.0k 1.0×	683 1.0×	431 0.8×	579 1.0×	92	5.0k
Haojie Jin China	30	2.7k 1.0×	1.8k 0.9×	541 0.8×	360 0.6×	411 0.7×	65	3.7k
Weiling He China	31	1.9k 0.7×	1.2k 0.6×	877 1.3×	557 1.0×	473 0.8×	94	3.7k
Yingchao Wang China	32	2.3k 0.9×	1.4k 0.7×	588 0.9×	375 0.7×	298 0.5×	148	3.7k
Lixia Xu China	30	1.6k 0.6×	966 0.5×	622 0.9×	286 0.5×	399 0.7×	106	2.8k
Yue Zhao China	37	1.9k 0.7×	1.4k 0.7×	1.2k 1.8×	510 0.9×	780 1.4×	140	4.0k
Gabi U. Dachs New Zealand	33	2.4k 0.9×	1.9k 1.0×	769 1.2×	234 0.4×	315 0.6×	85	4.5k
Yexiong Tan China	35	2.3k 0.9×	1.1k 0.5×	627 0.9×	347 0.6×	334 0.6×	77	3.5k
Xiangmin Tong China	27	1.9k 0.7×	1.3k 0.7×	601 0.9×	279 0.5×	909 1.6×	131	3.3k

Countries citing papers authored by Weiwei Tang

Since Specialization

Citations

This map shows the geographic impact of Weiwei Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tang more than expected).

Fields of papers citing papers by Weiwei Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tang. The network helps show where Weiwei Tang may publish in the future.

Co-authorship network of co-authors of Weiwei Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Weiwei Tang. A scholar is included among the top collaborators of Weiwei Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiwei Tang. Weiwei Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dai, Shipeng, Xin Su, Hongyu Wang, et al.. (2025). Phosphorus-32 microspheres: A dual-modality transarterial radioembolization approach for hepatocellular carcinoma therapy and Anti-PD1 immunotherapy potentiation. Materials Today Bio. 34. 102210–102210.

Li, Xiao, Xiaopei Hao, Yuliang Wang, et al.. (2024). GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing. Advanced Science. 11(39). e2402115–e2402115. 10 indexed citations

Shi, Dong-Min, et al.. (2024). Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduction and Targeted Therapy. 9(1). 192–192. 84 indexed citations breakdown →

Dai, Shipeng, Liu L, Yuliang Wang, et al.. (2024). MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell Death and Disease. 15(6). 411–411. 10 indexed citations

Huang, Chuan, Ying Zhang, Yongmei Hu, et al.. (2023). Prevalence and related factors of abdominal obesity among urban adults aged 35 to 79 years in southwest China. Frontiers in Public Health. 11. 1117897–1117897. 6 indexed citations

Zhao, Shihua, Jiayue Liu, Yanyan Wang, et al.. (2023). Polysaccharides from sea buckthorn (Hippophae rhamnoides L.) berries ameliorate cognitive dysfunction in AD mice induced by a combination of d‐gal and AlCl₃ by suppressing oxidative stress and inflammation reaction. Journal of the Science of Food and Agriculture. 103(12). 6005–6016. 22 indexed citations

Rong, Dawei, Yuliang Wang, Li Liu, et al.. (2023). GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. Journal for ImmunoTherapy of Cancer. 11(2). e005126–e005126. 17 indexed citations

Tang, Weiwei, Guangshun Sun, Gu‐Wei Ji, et al.. (2023). Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(11). e007030–e007030. 29 indexed citations

Sun, Guoqiang, Zhitao Li, Chunguang Zhou, et al.. (2022). Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. Journal of Oncology. 2022. 1–16. 11 indexed citations

10.

Li, Xiao, Liangliang Wu, Zhiying Zheng, et al.. (2022). Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. Journal of Oncology. 2022. 1–12. 4 indexed citations

11.

Lu, Hong, et al.. (2022). Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer. Journal of Clinical Laboratory Analysis. 36(6). e24447–e24447. 32 indexed citations

12.

Hao, Xiaopei, Yao Zhang, Xiaoli Shi, et al.. (2022). CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ. Journal of Experimental & Clinical Cancer Research. 41(1). 281–281. 57 indexed citations

13.

Sun, Guangshun, Hanyuan Liu, Jie Zhao, et al.. (2022). Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. Journal for ImmunoTherapy of Cancer. 10(12). e005655–e005655. 29 indexed citations

14.

Sun, Guangshun, Guoqiang Sun, Wubin Zheng, et al.. (2022). Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of Oncology. 2022. 1–12. 8 indexed citations

15.

Chen, Lu, Dawei Rong, Bingqing Hui, et al.. (2021). CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma. Cell Death Discovery. 7(1). 321–321. 23 indexed citations

16.

Li, Xiao, Guangshun Sun, Liangliang Wu, et al.. (2021). Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target. Journal of Oncology. 2021. 1–18. 12 indexed citations

17.

Rong, Dawei, Fan Wu, Lu Chen, et al.. (2021). m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression. Molecular Therapy — Nucleic Acids. 26. 637–648. 77 indexed citations

18.

Wu, Fan, Guoqiang Sun, Wubin Zheng, et al.. (2021). circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD‐L1 through NF‐κB pathway. Journal of Clinical Laboratory Analysis. 35(12). e24003–e24003. 17 indexed citations

19.

Fu, Jianjiang, et al.. (2020). Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer. SHILAP Revista de lepidopterología. 1 indexed citations

20.

Wang, Qian, Yanzhou Zhang, Handong Sun, et al.. (2018). Circ-DLG 1 promotes the proliferation of esophageal squamous cell carcinoma. OncoTargets and Therapy. Volume 11. 6723–6730. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact